Dietary Supplement Climea Forte 30tabs.

Product Information

In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen-alone or estrogen plus progestin when compared to placebo. The following adverse reactions have been identified during post-approval use of the Climara Forte transdermal system. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Genitourinary System

Do not exceed the recommended daily intake. The dietary supplement cannot be used as a substitute (replacement) of a varied diet. A varied diet and a healthy lifestyle are important for health.

Kiedy zachować szczególną ostrożność stosując Climea forte- tabletki?

There have not been sufficient numbers of geriatric women involved in clinical studies utilizing Climara Forte to determine whether those over 65 years of age differ from younger subjects in their response to Climara Forte. The Women’s Health Initiative Studies Climea Forte, a special supplement that affects the well-being and alleviate the discomfort of women, associated with menopause. The composition of the preparation is a double dose of soy isoflavones, which are classified as phytoestrogens - or plant counterparts of female hormones. Soy isoflavones are safe and have a mild effect on the endocrine women - without causing side effects. Due to the increased content of calcium and vitamin D3 Climea forte, also it allows you to maintain the proper structure and bone density. Enriched with the preparation that improves the appearance of the skin, and also relieves symptoms of fatigue and irritability associated with the menopause. Start therapy with 0.025 mg per day applied to the skin once weekly. Therapy should be started at the lowest effective dose and the shortest duration consistent with the treatment goals. Attempts to taper or discontinue the medication should be made at 3 to 6 month intervals. Treatment Of Hypoestrogenism Due To Hypogonadism, Castration, Or Primary Ovarian Failure

Climea forte содржи изофлавони од соја збогатени со лен, кој помага за контрола на телесната тежина и екстракт од хмељ, благодарение на кој ги ублажува симптомите на менопауза. Дополнително, додатокот во исхраната Climea forte содржи калциум и витамин Д3, кои помагаат за одржување на здрави коски и витамин Б6, придонесувајќи за намалување на замор и замор во менопаузата. Индикации isoflavones from soya - 60 mg Calcium - 400 mg, vitamin D3 - 5 mg, vitamin B6- 1.4 mg Vitamin E 12 mg equivalent of alpha-tocopherol, folic acid - 200 mg Other ingredients: Calcium carbonate cellulose (bulking), soy isoflavones, hydroxypropyl methylcellulose (glazing agent), extract of hops, succinate, D-alpha-tocopheryl acetate, magnesium salts of fatty acids (glazing agent), flaxseed ground, sodium carboxymethylcellulose, cross-linked (bulking agent), carbon titanium (dye), hydroxypropyl cellulose (glazing agent), cholecalciferol, pyridoxine hydrochloride, folic acid, quinoline yellow (color), sunset yellow FCF (dye), beeswax and carnauba wax (glazing agents) .This material includes yellow quinoline yellow and orange. The product contains soy and derivatives. https://www.termedia.pl/Wplyw-zmian-hormonalnych-zachodzacych-w-organizmie-kobiety-na-stan-skory,56,12608,0,0.html Table 1: Treatment-Emergent Adverse Reactions Reported at a Frequency of ≥ 5 Percent and More Frequent in Women Receiving Climara ForteStudies of the addition of a progestin for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone. Endometrial hyperplasia may be a precursor to endometrial cancer. Dose proportionality was demonstrated for the Climara Forte 6.5 cm² transdermal system as compared to the Climara Forte 12.5 cm² transdermal system in a 2-week crossover study with a 1-week washout period between the two-transdermal systems in 24 postmenopausal women. In women with pre-existing hypertriglyceridemia, estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis. Consider discontinuation of treatment if pancreatitis occurs. Hepatic Impairment And/Or Past History Of Cholestatic Jaundice

Should any adhesive remain on the skin after removal of the Climara Forte system, allow the area to dry for 15 minutes. Then gently rubbing the area with an oil-based cream or lotion should remove the adhesive residue. chinolinowa oraz żółcień pomarańczowa mogą mieć szkodliwy wpływ na aktywność i skupienie uwagi u dzieci.

Climara Forte should not be used during pregnancy. There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as oral contraceptives inadvertently during early pregnancy. Nursing Mothers handling complaints – legitimate interest of the Controller – Article 6(1)(f) of the GDPR. The basis for personal data processing will be Article 6(1)(b) of the GDPR, where necessary to perform a contract to which you are a party or to take steps at your request prior to entering into a contract. Increased plasma high-density lipoprotein (HDL) and HDL 2 cholesterol subfraction concentrations, reduced low-density lipoprotein (LDL) cholesterol concentration, and increased triglyceride levels. Clinically significant blood pressure increases have been reported during estrogen therapy, particularly in patients receiving high dosages or treated with oral contraceptive combinations having high progestational activity. Climara Forte should be applied immediately after opening the pouch and removing the protective liner.

Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. Excretion Estrogens may be poorly metabolized in patients with impaired liver function and should be administered with caution. Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be considered to reduce the risk of endometrial cancer. A woman without a uterus does not need a progestin. In some cases, however, hysterectomized women with a history of endometriosis may need a progestin.An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 times greater than in nonusers, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than 1 year. The greatest risk appears associated with prolonged use, with increased risks of 15-to 24-fold for 5 to 10 years or more. This risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued. If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization. Malignant Neoplasms Endometrial Cancer Estrogen is found in the the breast, uterine, ovarian, skin, prostate, bone, fat, and brain tissues. The main source of estrogen in adult women during the reproductive period of life is the ovarian follicle, which secretes 70 to 500 mcg of estradiol each day. After menopause, however, the majority of endogenous estrogen is produced by transformation of androstenedione (which is secreted by the adrenal cortex) to estrone in the peripheral tissues. Both estrone and its sulphate conjugated form, estrone sulphate, represent the most abundant estrogens found in postmenopausal women.